Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.15, FiscalAI reports. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The company had revenue of $55.39 million during the quarter, compared to analysts’ expectations of $51.65 million.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• Agios reported record third-quarter revenue of $55.4 million, more than four times the year-ago quarter, with $48.7 million from U.S. sales. The company attributed growth to AQVESME’s thalassemia launch and said U.S. revenue rose 20% sequentially.
• The FDA’s request for additional information on whether a REMS is needed for mitapivat in sickle cell disease extended the review by three months, moving the PDUFA goal date to February 1, 2027. Agios said it is discussing labeling and potential REMS elements with the agency and remains launch-ready.
• AQVESME had 619 completed start forms since launch—about 15% of Agios’s roughly 4,000-patient target population—with another 48 in process. The company reported approximately 75% of patients remained on therapy at six months and said demand is broadening to community practices and non-transfusion-dependent patients.
• Agios highlighted upcoming sickle cell data on sustained hemoglobin responses and post-hoc kidney and cardiac measures, while noting the organ findings are exploratory. It also expects to present AG-236 healthy-volunteer data at ASH, including effects lasting through six months, and plans to begin its PV phase II/III program by year-end.
• Agios ended the quarter with $907 million in cash and expects 2026 operating expenses to remain approximately flat year over year, excluding specified one-time items. It plans to reduce R&D headcount by more than 35% during 2026, with savings expected in 2027, and is targeting non-GAAP profitability in 2028.

Agios Pharmaceuticals Trading Up 1.6%

AGIO opened at $28.71 on Friday. The stock’s 50-day moving average price is $33.37 and its 200 day moving average price is $31.75. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -4.07 and a beta of 0.66.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. JPMorgan Chase & Co. boosted their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Bank of America increased their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Citigroup lifted their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Truist Financial reduced their price target on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $42.38.

Key Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $62 from $55 and maintained a “buy” rating, indicating substantial potential upside from the share price cited in the report. Analyst insights on Agios
• Positive Sentiment: Agios reported a Q3 loss of $1.09 per share, narrower than the cited consensus loss of $1.24, while revenue of $55.39 million exceeded the $51.65 million estimate. Mitapivat revenue surged more than fourfold, supporting the growth story. Q3 financial results and business update Mitapivat revenue and FDA decision timing
• Neutral Sentiment: The FDA decision on mitapivat for sickle cell disease is expected in February 2027. That creates a potential future catalyst, but the outcome remains uncertain. FDA decision timing
• Negative Sentiment: Despite beating estimates, Agios posted a quarterly loss, and it plans to eliminate more than 100 R&D roles. The cuts may reduce costs, but also underscore the company’s losses and restructuring needs. Report on planned R&D job cuts

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of Agios Pharmaceuticals stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the completion of the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at $2,059,570.05. The trade was a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 9,855 shares of company stock worth $371,112. Company insiders own 5.40% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.